title: Increased soluble p55 and p75 tumour necrosis factor-alpha receptors in patients with hepatitis C-associated mixed cryoglobulinaemia.
abstract: To investigate whether tumour necrosis factor alpha (TNFalpha) plays a role in the pathogenesis of hepatitis C virus-associated mixed cryoglobulinaemia (HCV-MC), we measured soluble TNFalpha and its soluble p55 (sTNFR1) and p75 (sTNFR2) receptors in the serum of patients with HCV-MC. TNFalpha, sTNFR1 and sTNFR2 were measured in the serum of 32 patients with HCV-MC, 18 patients with hepatitis C without MC (HCV) and 18 healthy volunteers, using specific immunoassays. Correlations between clinical and biological parameters and the concentrations of TNFalpha and sTNFRs were established by studying detailed clinical records of the 32 HCV-MC patients. Although higher, TNFalpha levels were not significantly different in HCV-MC patients compared with healthy or HCV controls. sTNFR1 and sTNFR2, however, were significantly higher in HCV-MC compared with controls or with HCV patients, and higher concentrations of sTNFR1 and sTNFR2 were observed in patients with severe visceral vasculitis, compared with patients with limited purpura. sTNFR1 concentrations positively correlated with fibrinogen levels but TNFalpha, sTNFR1 and sTNFR2 did not correlate with other biological parameters such as rheumatoid factor concentrations, CH50 or C4 values. These data suggest a role for TNFalpha in the pathogenesis of the immune complex-mediated vasculitis associated with HCV-MC.
authors.affiliation: INSERM U387, Hôpital Sainte-Marguerite, Marseille, France. gkaplanski@marseille.inserm.fr
authors.forename: G
authors.initials: G
authors.lastname: Kaplanski
authors.forename: V
authors.initials: V
authors.lastname: Marin
authors.forename: T
authors.initials: T
authors.lastname: Maisonobe
authors.forename: A
authors.initials: A
authors.lastname: Sbai
authors.forename: C
authors.initials: C
authors.lastname: Farnarier
authors.forename: P
authors.initials: P
authors.lastname: Ghillani
authors.forename: X
authors.initials: X
authors.lastname: Thirion
authors.forename: J M
authors.initials: JM
authors.lastname: Durand
authors.forename: J R
authors.initials: JR
authors.lastname: Harlé
authors.forename: P
authors.initials: P
authors.lastname: Bongrand
authors.forename: J C
authors.initials: JC
authors.lastname: Piette
authors.forename: P
authors.initials: P
authors.lastname: Cacoub
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000936:Antigen-Antibody Complex; D015703:Antigens, CD / Q000097:blood / Q000276:immunology*; D003449:Cryoglobulinemia / Q000097:blood / Q000209:etiology / Q000276:immunology*; D005260:Female; D006526:Hepatitis C / Q000097:blood / Q000150:complications / Q000276:immunology*; D006801:Humans; D008297:Male; D008875:Middle Aged; D018124:Receptors, Tumor Necrosis Factor / Q000097:blood / Q000276:immunology*; D047888:Receptors, Tumor Necrosis Factor, Type I; D047889:Receptors, Tumor Necrosis Factor, Type II; D018366:Vasculitis, Leukocytoclastic, Cutaneous / Q000209:etiology / Q000276:immunology
chemical_list: D000936:Antigen-Antibody Complex; D015703:Antigens, CD; D018124:Receptors, Tumor Necrosis Factor; D047888:Receptors, Tumor Necrosis Factor, Type I; D047889:Receptors, Tumor Necrosis Factor, Type II